Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Consulting agrmnt
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation

Sucampo Pharmaceuticals, Inc. (SCMP) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/23/2018 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/15/2018 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/15/2018 SC 13D/A Ueno Ryuji reports a 0% stake in Sucampo Pharmaceuticals, Inc.
02/14/2018 4 Kuno Sachiko (10% Owner) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Gifted 2,000,000 shares @ $0
Unknown transaction of 5,137,344 shares @ $18, valued at $92.5M
02/14/2018 4 Ueno Ryuji (10% Owner) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Gifted 600,000 shares @ $0
Gifted 2,000,000 shares @ $0
Unknown transaction of 5,406,585 shares @ $18, valued at $97.3M
02/13/2018 4 OCONNELL MAUREEN (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 5,130 shares @ $18, valued at $92.3k
Disposed/sold 30,000 options to buy @ $5.19, valued at $155.7k
Disposed/sold 20,000 options to buy @ $8.62, valued at $172.4k
Disposed/sold 20,000 options to buy @ $6.8, valued at $136k
Disposed/sold 20,000 options to buy @ $16.23, valued at $324.6k
Disposed/sold 10,000 options to buy @ $10.3, valued at $103k
02/13/2018 4 Walbert Timothy P (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 5,130 shares @ $18, valued at $92.3k
Disposed/sold 10,000 options to buy @ $10.3, valued at $103k
02/13/2018 4 Spiegel Robert J. (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 5,130 shares @ $18, valued at $92.3k
Disposed/sold 30,000 options to buy @ $14.04, valued at $421.2k
Disposed/sold 20,000 options to buy @ $16.23, valued at $324.6k
Disposed/sold 10,000 options to buy @ $10.3, valued at $103k
02/13/2018 4 Smith Karen L. (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 30,000 options to buy @ $10.95, valued at $328.5k
02/13/2018 4 Edick Paul R (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 14,930 shares @ $18, valued at $268.7k
Disposed/sold 10,000 options to buy @ $10.3, valued at $103k
02/13/2018 4 Donley Matthew Maxwell (EVP, Global HR, IT & Strategy) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Granted 36,975 shares @ $18, valued at $665.6k
Disposed/sold 150,000 options to buy @ $7.4, valued at $1.1M
Disposed/sold 25,000 options to buy @ $6.75, valued at $168.8k
Disposed/sold 28,000 options to buy @ $14.82, valued at $415k
Disposed/sold 75,000 options to buy @ $13.8, valued at $1M
Disposed/sold 101,000 options to buy @ $11.85, valued at $1.2M
02/13/2018 4 Greenleaf Peter (CEO) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 129,729 shares @ $18, valued at $2.3M
Disposed/sold 600,000 options to buy @ $8.49, valued at $5.1M
Disposed/sold 200,000 options to buy @ $5.9, valued at $1.2M
Disposed/sold 210,000 options to buy @ $14.82, valued at $3.1M
Disposed/sold 420,000 options to buy @ $13.8, valued at $5.8M
Disposed/sold 237,000 options to buy @ $11.85, valued at $2.8M
02/13/2018 4 JOHNSON JOHN (Director) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 5,130 shares @ $18, valued at $92.3k
Disposed/sold 30,000 options to buy @ $13.92, valued at $417.6k
Disposed/sold 20,000 options to buy @ $16.23, valued at $324.6k
Disposed/sold 10,000 options to buy @ $10.3, valued at $103k
02/13/2018 4 Kiener Peter A (Chief Science Officer) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 44,856 shares @ $18, valued at $807.4k
Disposed/sold 250,000 options to buy @ $8.33, valued at $2.1M
Disposed/sold 38,500 options to buy @ $14.82, valued at $570.6k
Disposed/sold 87,203 options to buy @ $13.8, valued at $1.2M
Disposed/sold 133,000 options to buy @ $11.85, valued at $1.6M
02/13/2018 4 Lichtlen Peter (Chief Medical Officer) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 24,000 shares @ $18, valued at $432k
Disposed/sold 78,200 options to buy @ $4.27, valued at $333.9k
Disposed/sold 78,200 options to buy @ $7.17, valued at $560.7k
Disposed/sold 25,000 options to buy @ $6.75, valued at $168.8k
Disposed/sold 44,000 options to buy @ $14.82, valued at $652.1k
Disposed/sold 44,000 options to buy @ $13.8, valued at $607.2k
Disposed/sold 45,000 options to buy @ $11.85, valued at $533.3k
02/13/2018 4 PFREUNDSCHUH PETER P. (CFO) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 263 shares @ $18, valued at $4.7k
Disposed/sold 150,000 options to buy @ $10.9, valued at $1.6M
02/13/2018 4 Bryan Jones W. (Sr. Vice Pres., BD & Licensing) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 5,139 shares @ $18, valued at $92.5k
Disposed/sold 150,000 options to buy @ $10.9, valued at $1.6M
02/13/2018 4 Meyenburg Jason Patrick (Chief Commercial Officer) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 30,228 shares @ $18, valued at $544.1k
Disposed/sold 150,000 options to buy @ $10.65, valued at $1.6M
02/13/2018 4 Driggs Alex (General Counsel & Corp. Sec.) has filed a Form 4 on Sucampo Pharmaceuticals, Inc.
Txns: Disposed/sold 6,084 shares @ $18, valued at $109.5k
Disposed/sold 25,600 options to buy @ $16.04, valued at $410.6k
Disposed/sold 24,150 options to buy @ $13.8, valued at $333.3k
Disposed/sold 11,068 options to buy @ $11.85, valued at $131.2k
02/13/2018 SC 13G/A ING GROEP NV reports a 0% stake in Sucampo Pharmaceuticals, Inc.
02/13/2018 SC 13G LSV ASSET MANAGEMENT reports a 5.3% stake in SUCAMPO PHARMACEUTICALS, INC.
02/13/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/13/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Sucampo Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Sucampo Pharmaceuticals, Inc",
"Supplemental Indenture, between Sucampo Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee"
02/13/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/13/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy